Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Immunovant price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
No price to sales ratio figures for Immunovant
Immunovant has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?